AssuredPartners Investment Advisors LLC acquired a new stake in Stryker Co. (NYSE:SYK - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 1,130 shares of the medical technology company's stock, valued at approximately $407,000.
Other large investors have also recently added to or reduced their stakes in the company. Kohmann Bosshard Financial Services LLC bought a new stake in Stryker in the 4th quarter valued at $25,000. Dunhill Financial LLC raised its stake in shares of Stryker by 94.9% in the third quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company's stock valued at $27,000 after purchasing an additional 37 shares in the last quarter. Rakuten Securities Inc. lifted its position in Stryker by 618.2% in the fourth quarter. Rakuten Securities Inc. now owns 79 shares of the medical technology company's stock worth $28,000 after purchasing an additional 68 shares during the period. Centricity Wealth Management LLC acquired a new stake in Stryker during the fourth quarter worth $30,000. Finally, BankPlus Trust Department bought a new stake in Stryker in the 4th quarter valued at $33,000. Institutional investors own 77.09% of the company's stock.
Wall Street Analyst Weigh In
SYK has been the topic of several recent research reports. StockNews.com lowered shares of Stryker from a "buy" rating to a "hold" rating in a research report on Thursday, March 6th. JMP Securities reaffirmed a "market perform" rating on shares of Stryker in a report on Tuesday, February 18th. Wells Fargo & Company increased their target price on Stryker from $427.00 to $435.00 and gave the stock an "overweight" rating in a report on Wednesday, January 29th. Stifel Nicolaus upped their price target on Stryker from $400.00 to $440.00 and gave the company a "buy" rating in a research report on Wednesday, January 29th. Finally, Needham & Company LLC reiterated a "buy" rating and set a $442.00 price objective on shares of Stryker in a research note on Friday, March 21st. Five analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $421.90.
Read Our Latest Stock Report on Stryker
Insider Transactions at Stryker
In other news, Director Ronda E. Stryker sold 201,392 shares of the stock in a transaction on Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the sale, the director now owns 3,642,075 shares of the company's stock, valued at $1,428,567,498. This represents a 5.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Allan C. Golston sold 2,458 shares of the stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now owns 14,895 shares of the company's stock, valued at approximately $5,705,827.65. This trade represents a 14.16 % decrease in their position. The disclosure for this sale can be found here. Insiders own 5.50% of the company's stock.
Stryker Trading Up 0.2 %
SYK traded up $0.88 during trading on Wednesday, reaching $374.18. 405,391 shares of the company's stock were exchanged, compared to its average volume of 1,290,650. The company's fifty day moving average price is $383.41 and its 200-day moving average price is $374.43. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.32 and a current ratio of 1.95. The firm has a market capitalization of $142.82 billion, a PE ratio of 48.27, a P/E/G ratio of 2.93 and a beta of 0.95. Stryker Co. has a fifty-two week low of $314.93 and a fifty-two week high of $406.19.
Stryker (NYSE:SYK - Get Free Report) last released its earnings results on Tuesday, January 28th. The medical technology company reported $4.01 earnings per share for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a return on equity of 23.58% and a net margin of 13.25%. During the same period last year, the business earned $3.46 EPS. As a group, equities analysts forecast that Stryker Co. will post 13.47 EPS for the current year.
Stryker Dividend Announcement
The company also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be issued a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a yield of 0.90%. Stryker's dividend payout ratio (DPR) is presently 43.30%.
About Stryker
(
Free Report)
Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.
Read More
Before you consider Stryker, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Stryker wasn't on the list.
While Stryker currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
